Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Sarcoma 3Other hematologic neoplasm 1Breast 1

Conditions

Breast Neoplasms 3Inflammatory Breast Neoplasms 1Cardiotoxicity 1

Interventions

Trastuzumab 8Doxorubicin 8Exercise 6Cyclophosphamide 6Echocardiography 5Carvedilol 5Docetaxel 4Tablets 2Silymarin 2Radiotherapy 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Exercise Test 2Epirubicin 2Bisoprolol 2Atorvastatin 2Anthracyclines 2sacubitril and valsartan sodium hydrate drug combination 1nicotinamide-beta-riboside 1mitoquinone 1epicatechin gallate 1empagliflozin 1dapagliflozin 1candesartan 1Watchful Waiting 1Therapeutics 1Taxes 1Tamoxifen 1Social Determinants of Health 1Secondary Prevention 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × Dexrazoxane × Breast × Clear all
NCT00016276 2013-01-16

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
396 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡